Our results suggest that CR may diminish IGF1/IGF1R signaling in two ways: by reducing circulating ligand, and by repressing Igf1r expression in a miR-15b-dependent manner in vivo (mammary tumors). The gene discussed is IGF1R; the disease is breast cancer.